<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04098068</url>
  </required_header>
  <id_info>
    <org_study_id>J1365 (Cohort D)</org_study_id>
    <secondary_id>MK-3475-016</secondary_id>
    <secondary_id>NA_00085756</secondary_id>
    <nct_id>NCT04098068</nct_id>
  </id_info>
  <brief_title>Study of MK-3475 (an Antibody That Blocks Negative Signals to T Cells) in Patients With Microsatellite Unstable (MSI) Tumors (Cohort D)</brief_title>
  <official_title>Phase 2 Study of MK-3475 (an Antibody That Blocks Negative Signals to T Cells) in Patients With Microsatellite Unstable (MSI) Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be looking at whether MK-3475 (an antibody that blocks negative signals to T
      cells) is effective (anti-tumor activity) and safe in patients with MSI (Microsatellite
      Unstable) negative cancer with a mutator phenotype.
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 9, 2018</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) in Patients with MSI (Microsatellite Unstable)-negative Solid Tumor Malignancies with a Mutator Phenotype</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS) in Patients at 28 Weeks Using RECIST 1.1(Response Evaluation Criteria In Solid Tumors)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate (DCR)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Experiencing Immune-related Toxicities (IRAEs)</measure>
    <time_frame>4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>High Tumor Mutation Burden</condition>
  <condition>High TMB (Tumor Mutation Burden)</condition>
  <condition>MSS (Microsatellite Unstable)</condition>
  <arm_group>
    <arm_group_label>MSI (Microsatellite Unstable) Negative with Mutator Phenotype</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MK-3475 (an Antibody That Blocks Negative Signals to T Cells)</intervention_name>
    <description>MK-3475 (an Antibody That Blocks Negative Signals to T Cells) 200 mg/kg flat dose every 21 days</description>
    <arm_group_label>MSI (Microsatellite Unstable) Negative with Mutator Phenotype</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with hypermutated MSI (Microsatellite Unstable) negative cancer

          -  Have measurable disease

          -  Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 1

          -  Adequate organ function as defined by study-specified laboratory tests

          -  Must use acceptable form of birth control through the study and for 28 days after
             final dose of study drug

          -  Signed informed consent form

          -  Willing and able to comply with study procedures

          -  Agree to have a biopsy of their cancer

          -  Patients with colon cancer must have received at least two prior cancer therapy
             regimens.

          -  Patients with other cancer types must have received at least one prior cancer therapy

          -  Progressive disease

        Exclusion Criteria:

          -  Patients with uncontrolled intercurrent illness, including but not limited to ongoing
             or active infection, systematic congestive heart failure, unstable angina pectoris,
             cardiac arrhythmia or psychiatric condition that would limit compliance with study
             requirements.

          -  Patients who have had chemotherapy or biological cancer therapy within 2 weeks prior
             to the first dose of study drug

          -  Patients who have had radiation within 2 weeks prior to the first dose of study drug

          -  Patients who have undergone major surgery within 4 weeks of dosing of investigational
             agent

          -  Patients who have received another investigational product or investigational device
             within 4 weeks prior to receiving study drug

          -  Patients who have received any of the following concomitant therapy: Interleukin-2
             (IL-2), interferon, or other non-study immunotherapy regimens, immunosuppressive
             agents, other investigational therapies or chronic use of systemic corticosteroids
             within one week prior to first dose of study drug

          -  Patients who have received a live vaccine within 4 weeks prior to or after any dose of
             MK-3475 (exception: inactivated flu vaccines)

          -  Patients who have received growth factors, including but not limited to
             granulocyte-colony stimulating factor (G-CSF), granulocyte macrophage-colony
             stimulating factor (GM-CSF), erythropoietin, etc. within 2 weeks of study drug
             administration

          -  Patient who have had prior treatment with anti-PD-1 (anti-programmed cell death
             protein 1), anti-PD-L1, anti-PD-L2, anti-CD137, anti-OX-40, anti-CD40, or anti-CTLA-4
             antibodies

          -  Patients with history of any autoimmune disease:inflammatory bowel disease, (including
             ulcerative colitis and Crohn's Disease), rheumatoid arthritis, systemic progressive
             sclerosis (scleroderma), systemic lupus erythematosus (SLE) autoimmune vasculitis,
             central nervous system (CNS) or motor neuropathy considered to be of autoimmune
             origin.

          -  Patients who have known history of infection with HIV, hepatitis B, or hepatitis C

          -  Patients with evidence of interstitial lung disease

          -  Systemically active steroid use

          -  Patients on home oxygen

          -  Patients with oxygen saturation of &lt;92% on room air by pulse oximetry

          -  Pregnant or lactating

          -  Conditions, including alcohol or drug dependence, or intercurrent illness that would
             affect the patient's ability to comply with study visits and procedures

          -  Patient with known active central nervous system metastases and/or carcinomatous
             meningitis.

          -  Patients with primary brain tumors.

          -  Requires any other form of systemic or localized antineoplastic therapy while on study

          -  Has any tissue or organ allograft

          -  Patients with history of allogeneic hematopoeitic stem cell transplant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Dung Le, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sidney Kimmel Comprehensive Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dana-Farber Cancer Institute</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania, Abramson Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Cancer Institute</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>September 19, 2019</study_first_submitted>
  <study_first_submitted_qc>September 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2019</study_first_posted>
  <last_update_submitted>July 24, 2020</last_update_submitted>
  <last_update_submitted_qc>July 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>BRAF pv600E (human gene that encodes a protein called B-Raf)</keyword>
  <keyword>TGFBR2 (transforming growth factor-beta (TGF-Î²) receptor type 2)</keyword>
  <keyword>Mutation load</keyword>
  <keyword>Tumor mutation load</keyword>
  <keyword>Mutation burden</keyword>
  <keyword>Tumor mutation burden (TMB)</keyword>
  <keyword>Hypermutation</keyword>
  <keyword>POLE</keyword>
  <keyword>MSI Negative with Mutator Phenotype (High Tumor Mutation Burden)</keyword>
  <keyword>TMB (Tumor Mutation Burden)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

